Aptose Biosciences (TSE:APS) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Aptose Biosciences (TSE:APSGet Free Report) (NASDAQ:APTO) issued its quarterly earnings results on Tuesday. The biotechnology company reported C($1.96) EPS for the quarter, topping the consensus estimate of C($1.98) by C$0.02, reports.

Aptose Biosciences Trading Up 9.3 %

TSE APS opened at C$2.24 on Friday. Aptose Biosciences has a 12 month low of C$1.85 and a 12 month high of C$13.35. The stock has a 50-day simple moving average of C$2.43 and a 200 day simple moving average of C$3.18. The company has a current ratio of 1.59, a quick ratio of 5.41 and a debt-to-equity ratio of 14.27. The company has a market capitalization of C$35.19 million, a PE ratio of -0.21 and a beta of 1.44.

Aptose Biosciences Company Profile

(Get Free Report)

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Further Reading

Earnings History for Aptose Biosciences (TSE:APS)

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.